Objective: We evaluated atrial fibrillation (AF) patients' perceptions of anticoagulation treatment with dabigatran or a vitamin K antagonist (VKA) for stroke prevention, according to accepted indications. Methods: The RE-SONANCE observational, prospective, multicentre, international study used the validated Perception on Anticoagulant Treatment Questionnaire (PACT-Q) to assess patients with AF already taking a VKA who were switched to dabigatran (cohort A), and newly diagnosed patients initiated on either dabigatran or a VKA (cohort B). Visit 1 (V1) was at baseline, and visit 2 (V2) and visit 3 (V3) were at 30-45 and 150-210 days after baseline, respectively. Primary outcomes were treatment satisfaction and convenience in cohort A at V2 and V3 versus baseline, and in cohort B for dabigatran and a VKA at V2 and V3. Results: The main analysis set comprised 4100 patients in cohort A and 5365 in cohort B (dabigatran: 3179; VKA: 2186). In cohort A, PACT-Q2 improved significantly (p<0.001 for all) for treatment convenience (mean change V1 vs V2=20.72; SD=21.50; V1 vs V3=24.54; SD=22.85) and treatment satisfaction (mean change V1 vs V2=17.60; SD=18.76; V1 vs V3=21.04; SD=20.24). In cohort B, mean PACT-Q2 scores at V2 and V3 were significantly higher (p<0.001 for all) for dabigatran versus a VKA for treatment convenience (V2=18.38; SE =0.51; V3=23.34; SE=0.51) and satisfaction (V2=15.88; SE=0.39; V3=19.01; SE=0.41). Conclusions: Switching to dabigatran from long-term VKA therapy or newly initiated dabigatran is associated with improved patient treatment convenience and satisfaction compared with VKA therapy.

1st Department of Cardiology Silesian Medical University Katowice Poland

1st Department of Internal Medicine Tolna County 'Balassa Janos' Teaching Hospital Szekszard Hungary

Biostatistics and Data Sciences Boehringer Ingelheim Pharmaceuticals Inc Ridgefield Connecticut USA

Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria

Cardiology Department Riga Stradins University Riga Latvia

Cardiology University and Emergency Hospital of Bucharest Bucharest Other Romania

Clalit Health Services Bonen Clinic Haifa Israel

Department of Cardiology Clinical Centre of Serbia Belgrade Serbia

Department of Cardiology General Hospital Celje Celje Slovenia

Department of Cardiology National Cardiology Hospital Sofia Bulgaria

Department of Cardiology North Estonia Medical Centre Foundation Tallinn Estonia

Department of Cardiology University Clinic of Internal Medicine 2 Medical University of Vienna Vienna Austria

Department of Internal Medicine 1 M Sechenov 1st Moscow State Medical University Moscow Russian Federation

Faculty of Medicine in Hradec Kralové Charles University Broumov Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc20025137

003      

CZ-PrNML

005      

20201222153720.0

007      

ta

008      

201125s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1136/openhrt-2019-001202 $2 doi

035    __

$a (PubMed)32257246

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Vinereanu, Dragos $u Cardiology, University and Emergency Hospital of Bucharest, Bucharest, Other, Romania.

245    10

$a Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study) / $c D. Vinereanu, D. Napalkov, J. Bergler-Klein, B. Benczur, M. Ciernik, N. Gotcheva, A. Medvedchikov, P. Põder, D. Simic, A. Skride, W. Tang, M. Trusz-Gluza, J. Vesely, T. Vishnepolsky, M. Vrabec,

520    9_

$a Objective: We evaluated atrial fibrillation (AF) patients' perceptions of anticoagulation treatment with dabigatran or a vitamin K antagonist (VKA) for stroke prevention, according to accepted indications. Methods: The RE-SONANCE observational, prospective, multicentre, international study used the validated Perception on Anticoagulant Treatment Questionnaire (PACT-Q) to assess patients with AF already taking a VKA who were switched to dabigatran (cohort A), and newly diagnosed patients initiated on either dabigatran or a VKA (cohort B). Visit 1 (V1) was at baseline, and visit 2 (V2) and visit 3 (V3) were at 30-45 and 150-210 days after baseline, respectively. Primary outcomes were treatment satisfaction and convenience in cohort A at V2 and V3 versus baseline, and in cohort B for dabigatran and a VKA at V2 and V3. Results: The main analysis set comprised 4100 patients in cohort A and 5365 in cohort B (dabigatran: 3179; VKA: 2186). In cohort A, PACT-Q2 improved significantly (p<0.001 for all) for treatment convenience (mean change V1 vs V2=20.72; SD=21.50; V1 vs V3=24.54; SD=22.85) and treatment satisfaction (mean change V1 vs V2=17.60; SD=18.76; V1 vs V3=21.04; SD=20.24). In cohort B, mean PACT-Q2 scores at V2 and V3 were significantly higher (p<0.001 for all) for dabigatran versus a VKA for treatment convenience (V2=18.38; SE =0.51; V3=23.34; SE=0.51) and satisfaction (V2=15.88; SE=0.39; V3=19.01; SE=0.41). Conclusions: Switching to dabigatran from long-term VKA therapy or newly initiated dabigatran is associated with improved patient treatment convenience and satisfaction compared with VKA therapy.

650    _2

$a aplikace orální $7 D000284

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925

650    _2

$a antithrombiny $x aplikace a dávkování $x škodlivé účinky $7 D000991

650    _2

$a fibrilace síní $x komplikace $x diagnóza $x farmakoterapie $7 D001281

650    _2

$a dabigatran $x aplikace a dávkování $x škodlivé účinky $7 D000069604

650    _2

$a náhrada léků $7 D057915

650    _2

$a ženské pohlaví $7 D005260

650    12

$a zdraví - znalosti, postoje, praxe $7 D007722

650    _2

$a krvácení $x chemicky indukované $7 D006470

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    12

$a spokojenost pacientů $7 D017060

650    _2

$a prospektivní studie $7 D011446

650    _2

$a ochranné faktory $7 D065840

650    _2

$a rizikové faktory $7 D012307

650    _2

$a cévní mozková příhoda $x diagnóza $x etiologie $x prevence a kontrola $7 D020521

650    _2

$a časové faktory $7 D013997

650    _2

$a výsledek terapie $7 D016896

650    _2

$a vitamin K $x antagonisté a inhibitory $7 D014812

650    _2

$a mladý dospělý $7 D055815

651    _2

$a Evropa $7 D005060

651    _2

$a Izrael $7 D007557

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a pozorovací studie $7 D064888

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Napalkov, Dmitry $u Department of Internal Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

700    1_

$a Bergler-Klein, Jutta $u Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

700    1_

$a Benczur, Bela $u 1st Department of Internal Medicine (Cardiology/Nephrology), Tolna County 'Balassa Janos' Teaching Hospital, Szekszard, Hungary.

700    1_

$a Ciernik, Martin $u Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.

700    1_

$a Gotcheva, Nina $u Department of Cardiology, National Cardiology Hospital, Sofia, Bulgaria.

700    1_

$a Medvedchikov, Alexey $u Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.

700    1_

$a Põder, Pentti $u Department of Cardiology, North Estonia Medical Centre Foundation, Tallinn, Estonia.

700    1_

$a Simic, Dragan $u Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia.

700    1_

$a Skride, Andris $u Cardiology Department, Riga Stradins University, Riga, Latvia.

700    1_

$a Tang, Wenbo $u Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.

700    1_

$a Trusz-Gluza, Maria $u First Department of Cardiology, Silesian Medical University, Katowice, Poland.

700    1_

$a Vesely, Jiri $u Faculty of Medicine in Hradec Kralové, Charles University, Broumov, Czech Republic.

700    1_

$a Vishnepolsky, Tatiana $u Clalit Health Services, Bonen Clinic, Haifa, Israel.

700    1_

$a Vrabec, Mirej $u Department of Cardiology, General Hospital Celje, Celje, Slovenia.

773    0_

$w MED00186378 $t Open heart $x 2053-3624 $g Roč. 7, č. 1 (2020), s. e001202

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32257246 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20201222153716 $b ABA008

999    __

$a ok $b bmc $g 1599282 $s 1115823

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 7 $c 1 $d e001202 $e 20200324 $i 2053-3624 $m Open heart $n Open Heart $x MED00186378

LZP    __

$a Pubmed-20201125